-

Cure Rare Disease Welcomes Leading Experts to Scientific Advisory Board

WOODBRIDGE, Conn.--(BUSINESS WIRE)--Cure Rare Disease (CRD) - a nonprofit biotechnology company focused on developing treatments for ultra-rare diseases - announces the appointment of leading experts in the fields of gene therapy and neuromuscular disorders to its Scientific Advisory Board (SAB).

As part of their role, SAB members help advance CRD's preclinical and clinical development of its gene therapy and antisense oligonucleotide (ASO) programs, providing strategic advice on scientific, regulatory, and clinical matters.

The members of the newly appointed SAB bring a wealth of expertise and experience in the areas of treatment and therapeutic development for neuromuscular diseases. They include:

  • Nick Johnson, M.D., M.Sci., FAAN (Board Chair)
    Adult Neurology, Neuromuscular Vice Chair, Research Associate Professor, VCU School of Medicine
  • Carsten Bonnemann, M.D.
    Senior Investigator, Neuromuscular and Neurogenetic Disorders of Childhood Section, NIH Intramural Research Program
  • Elizabeth McNally, M.D., Ph.D.
    Professor and Director, Center for Genetic Medicine Professor of Medicine
    (Cardiology) and Biochemistry and Molecular Genetics, Northwestern Feinberg School of Medicine
  • Perry Shieh, M.D., PhD
    Neurology, Neuromuscular Medicine, UCLA Health
  • Alan Beggs, Ph.D.
    Director, The Manton Center for Orphan Disease Research
    Sir Edwin and Lady Manton Professor of Pediatrics, Harvard Medical School

"CRD is honored to welcome these esteemed experts in gene therapy and neuromuscular disorders to our scientific advisory board," said Rich Horgan, MBA, Founder and CEO of CRD. "Their insights and guidance will be critical as we continue to advance our programs and work towards our goal of providing life-saving treatments to individuals with rare diseases."

CRD currently has 19 therapeutic programs under development, including potential treatments for Duchenne muscular dystrophy, Limb Girdle muscular dystrophy, SCA3 and ADSSL1 distal myopathy, as well as a program aimed at overcoming the challenges of neutralizing antibodies in gene therapy delivery. Collectively, these programs offer pragmatic hope of treatment to more than 200,000 Americans living with rare and ultra-rare diseases.

About Cure Rare Disease
Cure Rare Disease (CRD) is a nonprofit biotechnology company focused on the development of genetic medicines for rare and ultra- rare diseases. CRD is committed to accelerating the development of treatments for individuals with rare diseases through a patient-centric approach to research and development. The company's programs include gene therapy and antisense oligonucleotide (ASO) treatments for a range of rare diseases. For more information, please visit https://www.cureraredisease.org/.

Contacts

Suzanne Day
Vice President, Greenough
804.387.0760 (mobile)
617.275.6521 (office)
media@cureRD.org

Industry:

Cure Rare Disease

Details
Headquarters: Boston, USA
CEO: Richard Horgan
Employees: 5
Organization: NON
Release Versions
English

Contacts

Suzanne Day
Vice President, Greenough
804.387.0760 (mobile)
617.275.6521 (office)
media@cureRD.org

Social Media Profiles
Cure Rare Disease Facebook Account
Cure Rare Disease Instagram Account
Cure Rare Disease LinkedIn Account
Cure Rare Disease Twitter Account
Cure Rare Disease YouTube Account
More News From Cure Rare Disease

Cure Rare Disease Secures FDA Orphan Drug Designation for Investigational Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type R9 (LGMD2i/R9)

WOODBRIDGE, Conn.--(BUSINESS WIRE)--Cure Rare Disease (CRD), a 501(c)(3) nonprofit biotechnology company developing genetic therapies for ultra-rare neuromuscular diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for its investigational therapy, CRD-003, for the treatment of congenital muscular dystrophy caused by biallelic mutations in the FKRP gene (Limb-Girdle Muscular Dystrophy Type R9, LGMD2i/R9). The investigational therap...

Cure Rare Disease Receives FDA Feedback on Limb-Girdle 2i/R9 Gene Therapy Program Following Successful Pre-IND Meeting

WOODBRIDGE, Conn.--(BUSINESS WIRE)--Cure Rare Disease (CRD), a nonprofit biotechnology organization developing genetic therapies for ultra-rare diseases, today announced the successful completion of a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) regarding its investigational gene therapy program for Limb-Girdle Muscular Dystrophy type 2I/R9 (LGMDR9). The LGMDR9 program, known as CRD-003, utilizes a novel, liver de-targeting, muscle tropic capsi...

Cure Rare Disease Welcomes New Scientific and Strategic Leaders to Advance Therapies for Ultra-Rare Conditions

WOODBRIDGE, Conn.--(BUSINESS WIRE)--Cure Rare Disease (CRD), a clinical-stage nonprofit biotechnology organization developing genetic therapies for ultra-rare conditions, is proud to announce the appointment of Keith Sutton, PhD, as Chief Science Officer and the addition of Michelle Werner to its Board of Directors. These strategic additions bring deep scientific expertise and seasoned biopharmaceutical leadership to CRD as the organization continues to advance therapeutic development for rare...
Back to Newsroom